Teva, Catalyst and Firdapse

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA regarding the Firdapse (amifampridine) patent litigation.
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.
Catalyst settles with Teva, staving off Firdapse generic until 2035
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med Firdapse, Catalyst Pharmaceutical has repeatedly emerged triumphant over its d | Thanks to a new settlement with Catalyst,
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases,
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock was recently at $22.
Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva (TEVA) that would delay the launch of a generic version of its drug Firdapse until at least 2035.
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
Hosted on MSN8m
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals
Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Shares of Catalyst Pharmaceuticals Inc. CPRX slipped 3.27% to $19.53 Tuesday, on what proved to be an all-around rough ...
Zacks.com on MSN1d
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
bovnews1d
Analysts Predict a $35 Target for Catalyst Pharmaceuticals Inc (CPRX) Stock—What Could Drive It There?
Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a three-day losing streak.
Benzinga.com22h
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Quotes, Forecast and News Summary
Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...
Forbes7d
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...
Catalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating with 58.7% Upside Potential
Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...